Anupam Rasayan Reports Q2 EBITDA and Margin Expansion

Market snapshot: Anupam Rasayan reported Q2 EBITDA of ₹187 crore against ₹136 crore YoY and an EBITDA margin of 23.23% versus 18.57% YoY (as stated in the source alert; not independently verified). Grounded exchange disclosures demonstrate operational stability building on strong Q1 FY27 momentum and active multi-year supply partnerships.

Data Snapshot

• Q1 FY27 Total Revenue stood at ₹667.5 crore, up 36% YoY from ₹490.7 crore.
• Q1 FY27 Consolidated EBITDA reached ₹174.9 crore, up 35% YoY with an EBITDA margin of 26.2%.
• Acquisition of 48.2% controlling stake in Bliss GVS Pharma completed at ₹299 per share.

What's Changed

• Q1 FY27 revenue expanded 36% YoY to ₹667.5 crore compared to ₹490.7 crore in Q1 FY26.
• Q1 FY27 EBITDA grew 35% YoY to ₹174.9 crore compared to ₹129.2 crore in Q1 FY26.

Key Takeaways

• Operational profitability shows resilience driven by specialized chemical synthesis.
• Strategic expansion into downstream formulations via Bliss GVS Pharma broadens addressable market opportunities.
• Long-term custom synthesis contracts provide steady revenue visibility for coming quarters.

SAHI Perspective

Anupam Rasayan's operating profile reflects steady execution within custom synthesis and fluorination chemistry. Margins remain supported by high-value specialty chemical molecules and key global customer commitments.

Market Implications

Sustained operational margins reinforce investor confidence in specialty chemical contract execution. Continued integration of recent strategic acquisitions could unlock incremental operating leverage.

Trading Signals

Market Bias: Bullish

Positive bias reflects operational stability, grounded Q1 FY27 EBITDA growth of 35% YoY to ₹174.9 crore, and secure multi-year customer supply agreements.

Overweight: Specialty Chemicals, CDMO & Custom Synthesis

Trigger Factors:

• Ramp-up of execution on the 6-year US industrial major supply contract
• Synergy realization from Bliss GVS Pharma integration
• Raw material input cost trends in key chemical building blocks

Time Horizon: Medium-term (3-12 months)

Industry Context

India's specialty chemical sector continues to benefit from global supply chain diversification and rising demand for custom synthesis capabilities in agrochemicals and pharmaceuticals.

Key Risks to Watch

• Volatility in raw material input costs and chemical intermediaries
• Integration timelines for acquired pharmaceutical formulation entities
• Global macroeconomic fluctuations affecting end-market demand

Recent Developments

In September 2026, Anupam Rasayan secured a 6-year chemical supply contract with a US-headquartered global industrial major. In the same month, the company completed consideration payment for acquiring a 48.2% controlling stake in Bliss GVS Pharma Limited at ₹299 per share.

Closing Insight

Consistent contract wins and disciplined chemical manufacturing execution position Anupam Rasayan well to capture high-margin specialty market share.

High Performance Trading with SAHI.